1. Home
  2. BUSE vs ANIP Comparison

BUSE vs ANIP Comparison

Compare BUSE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Busey Corporation

BUSE

First Busey Corporation

HOLD

Current Price

$25.31

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

ANIP

ANI Pharmaceuticals Inc.

HOLD

Current Price

$73.62

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BUSE
ANIP
Founded
1868
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
BUSE
ANIP
Price
$25.31
$73.62
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$27.00
$107.33
AVG Volume (30 Days)
596.0K
285.9K
Earning Date
04-28-2026
05-11-2026
Dividend Yield
4.01%
N/A
EPS Growth
N/A
419.23
EPS
1.47
3.32
Revenue
$719,584,000.00
$206,547,000.00
Revenue This Year
$23.61
$44.10
Revenue Next Year
$3.69
$13.18
P/E Ratio
$31.30
$35.93
Revenue Growth
55.66
2.47
52 Week Low
$18.40
$56.71
52 Week High
$27.65
$99.50

Technical Indicators

Market Signals
Indicator
BUSE
ANIP
Relative Strength Index (RSI) 45.09 35.37
Support Level $23.53 $62.89
Resistance Level $26.08 $85.12
Average True Range (ATR) 0.75 2.78
MACD -0.18 -0.30
Stochastic Oscillator 12.69 12.37

Price Performance

Historical Comparison
BUSE
ANIP

About BUSE First Busey Corporation

First Busey Corporation is a financial holding company, whose subsidiaries provides retail and commercial banking services, remittance processing, and offers financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech and Wealth Management. The banking segment generates a vast majority of its revenue.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Share on Social Networks: